Indy Hematology Review
Avatar

State of the Art in 2024: Emerging Therapies in Hematologic Malignancies

By Indy Hematology Review FEATURING Ruemu Birhiray
By Indy Hematology Review FEATURING Ruemu Birhiray
205 views
April 16, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
21:20
Cleveland Clinic Rheumatology

How do I Recognize and Treat the VEXAS Syndrome?

Feat. P. Grayson
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
30:41
Icahn School of Medicine at Mount Sinai

How to Approach Anemia

Feat. C. Cromwell
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
61:16
Scripps Health

Anemia: Beyond Iron Deficiency!

Feat. A. Goodman
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
04:16
Luke Fletcher

Efficacy and Safety of Asciminib in Ph+ CML

19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
06:33
Christopher Flowers

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
11:12
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AV…

Feat. A. Herrera
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach